Regeneron Pharmaceuticals will buy Genetic Test company 23andme The companies said on Monday that keeping $ 256 million through a bankruptcy auction.
Regeneron said that it will consider 23DME privacy policies and the laws in force regarding the use of customer data and that it is ready for detailing its intended use of data to the supervisor appointed by the court. Companies expect to close the deal in the third quarter.
The bankruptcy procedures, which were presented in March, have attracted the audit of legislators who warned that millions of genetic data for customers can be sold to non -conscience buyers.
After promoting the newsletter
Last month, 23andme agreed to allow the supervisor appointed by the court to deal with the company for genetic information for customers and security policies during bankruptcy.
As part of the agreement, Regeneron will get all 23ndme units, with the exception of the Lemonaid Health Service Health service, which plans the genetic tests company to finish. After the treatment is complete, 23andme will continue to work as a direct or indirect unit that is fully owned by Regeneron, the companies reported.
The company collected genetic data from 15 million customers who requested DNA testing groups online and provided saliva samples. It was struggling with the weak demand for their grandparents testing groups and the repercussions of data breach in 2023, which were exposed to millions of genetic data to customers.
